- Home
- GCT vs PRAX Comparison
GCT vs PRAX Comparison
Compare GCT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCT
- PRAX
- Stock Information
- Founded
- GCT 2019
- PRAX 2015
- Country
- GCT United States
- PRAX United States
- Employees
- GCT N/A
- PRAX N/A
- Industry
- GCT Catalog/Specialty Distribution
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- GCT Consumer Discretionary
- PRAX Health Care
- Exchange
- GCT Nasdaq
- PRAX Nasdaq
- Market Cap
- GCT 798.3M
- PRAX 950.8M
- IPO Year
- GCT 2022
- PRAX 2020
- Fundamental
- Price
- GCT $29.55
- PRAX $38.68
- Analyst Decision
- GCT Buy
- PRAX Strong Buy
- Analyst Count
- GCT 2
- PRAX 9
- Target Price
- GCT $24.00
- PRAX $94.44
- AVG Volume (30 Days)
- GCT 1.1M
- PRAX 402.3K
- Earning Date
- GCT 11-06-2025
- PRAX 11-05-2025
- Dividend Yield
- GCT N/A
- PRAX N/A
- EPS Growth
- GCT 19.25
- PRAX N/A
- EPS
- GCT 3.31
- PRAX N/A
- Revenue
- GCT $1,193,610,000.00
- PRAX $7,765,000.00
- Revenue This Year
- GCT $4.39
- PRAX N/A
- Revenue Next Year
- GCT $5.28
- PRAX $25.00
- P/E Ratio
- GCT $8.77
- PRAX N/A
- Revenue Growth
- GCT 21.20
- PRAX 338.45
- 52 Week Low
- GCT $11.17
- PRAX $26.70
- 52 Week High
- GCT $34.50
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- GCT 58.65
- PRAX 30.76
- Support Level
- GCT $25.15
- PRAX $37.19
- Resistance Level
- GCT $30.12
- PRAX $40.69
- Average True Range (ATR)
- GCT 1.31
- PRAX 2.33
- MACD
- GCT -0.03
- PRAX -0.70
- Stochastic Oscillator
- GCT 85.99
- PRAX 13.43
About GCT GigaCloud Technology Inc
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.